Consistent with the data about the tumor volume, the combination of L-pampoTM with the PD-L1 inhibitor group improved the survival rate compared to the control and PD-L1 groups (Figure 6C), supporting the notion that L-pampoTM can be a potent cancer vaccine adjuvant and a synergistic partner of ICIs for cancer treatment. This evidence concerns the gene CD274 and neoplasm.